Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Eshbal Acquires a 55% Interest in Dare to Be Different Foods (click to learn more) CSE: ALEN.U — AI Meets Digital Health (click to learn more) What’s Behind Cannabis Stock HERB? (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Polyrizon Ltd PLRZ

Healthcare Biotechnology
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a... see more

Recent & Breaking News (NDAQ:PLRZ)

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

GlobeNewswire 22 hours ago

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

GlobeNewswire 4 days ago

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

GlobeNewswire 4 days ago

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

GlobeNewswire 6 days ago

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX(TM) Allergy Blocker

GlobeNewswire January 22, 2026

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

GlobeNewswire January 13, 2026

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX(TM)

GlobeNewswire January 8, 2026

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

GlobeNewswire January 5, 2026

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

GlobeNewswire January 2, 2026

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

GlobeNewswire December 29, 2025

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

GlobeNewswire December 19, 2025

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

GlobeNewswire December 11, 2025

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

GlobeNewswire December 8, 2025

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

GlobeNewswire December 4, 2025

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

GlobeNewswire December 3, 2025

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

GlobeNewswire December 2, 2025

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

GlobeNewswire November 6, 2025

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

GlobeNewswire October 6, 2025

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

GlobeNewswire September 19, 2025

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

GlobeNewswire September 12, 2025

Podcasts